AU2013214776B2 - Adenoviruses expressing heterologous tumor-associated antigens - Google Patents
Adenoviruses expressing heterologous tumor-associated antigens Download PDFInfo
- Publication number
- AU2013214776B2 AU2013214776B2 AU2013214776A AU2013214776A AU2013214776B2 AU 2013214776 B2 AU2013214776 B2 AU 2013214776B2 AU 2013214776 A AU2013214776 A AU 2013214776A AU 2013214776 A AU2013214776 A AU 2013214776A AU 2013214776 B2 AU2013214776 B2 AU 2013214776B2
- Authority
- AU
- Australia
- Prior art keywords
- adenovirus
- nucleic acid
- cancer
- recombinant oncolytic
- immunogenic peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 154
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 106
- 239000000427 antigen Substances 0.000 title claims abstract description 85
- 108091007433 antigens Proteins 0.000 title claims abstract description 85
- 102000036639 antigens Human genes 0.000 title claims abstract description 85
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 59
- 108090000623 proteins and genes Proteins 0.000 claims description 74
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 54
- 230000002163 immunogen Effects 0.000 claims description 48
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 201000011510 cancer Diseases 0.000 claims description 39
- 230000000174 oncolytic effect Effects 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 26
- 206010018338 Glioma Diseases 0.000 claims description 17
- 102000018697 Membrane Proteins Human genes 0.000 claims description 17
- 108010052285 Membrane Proteins Proteins 0.000 claims description 17
- -1 midkin Proteins 0.000 claims description 15
- 241001135569 Human adenovirus 5 Species 0.000 claims description 12
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 9
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 9
- 238000012737 microarray-based gene expression Methods 0.000 claims description 9
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 239000000835 fiber Substances 0.000 claims description 6
- 108700026758 Adenovirus hexon capsid Proteins 0.000 claims description 5
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 4
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 4
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims description 4
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims description 4
- 108060008724 Tyrosinase Proteins 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 3
- 102100027106 BRCA1-associated protein Human genes 0.000 claims description 3
- 108060000903 Beta-catenin Proteins 0.000 claims description 3
- 102000015735 Beta-catenin Human genes 0.000 claims description 3
- 101150012716 CDK1 gene Proteins 0.000 claims description 3
- 102100026548 Caspase-8 Human genes 0.000 claims description 3
- 108090000538 Caspase-8 Proteins 0.000 claims description 3
- 102100038281 Cytospin-A Human genes 0.000 claims description 3
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 3
- 102000003817 Fos-related antigen 1 Human genes 0.000 claims description 3
- 108090000123 Fos-related antigen 1 Proteins 0.000 claims description 3
- 102100039717 G antigen 1 Human genes 0.000 claims description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 3
- 102100034153 Golgin subfamily A member 6B Human genes 0.000 claims description 3
- 102100031624 Heat shock protein 105 kDa Human genes 0.000 claims description 3
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 3
- 101000984746 Homo sapiens BRCA1-associated protein Proteins 0.000 claims description 3
- 101000944524 Homo sapiens Bombesin receptor-activated protein C6orf89 Proteins 0.000 claims description 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 3
- 101000884816 Homo sapiens Cytospin-A Proteins 0.000 claims description 3
- 101100449143 Homo sapiens GOLGA6B gene Proteins 0.000 claims description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 3
- 101000866478 Homo sapiens Heat shock protein 105 kDa Proteins 0.000 claims description 3
- 101001001418 Homo sapiens Inhibitor of growth protein 4 Proteins 0.000 claims description 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 3
- 101000979578 Homo sapiens NK-tumor recognition protein Proteins 0.000 claims description 3
- 101000801664 Homo sapiens Nucleoprotein TPR Proteins 0.000 claims description 3
- 101100029612 Homo sapiens PHF20 gene Proteins 0.000 claims description 3
- 101000662592 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 claims description 3
- 101000872170 Homo sapiens Polycomb complex protein BMI-1 Proteins 0.000 claims description 3
- 101000583459 Homo sapiens Progesterone-induced-blocking factor 1 Proteins 0.000 claims description 3
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 claims description 3
- 101000727472 Homo sapiens Reticulon-4 Proteins 0.000 claims description 3
- 101000823796 Homo sapiens Y-box-binding protein 1 Proteins 0.000 claims description 3
- 102100035677 Inhibitor of growth protein 4 Human genes 0.000 claims description 3
- 102100023123 Mucin-16 Human genes 0.000 claims description 3
- 102100023384 NK-tumor recognition protein Human genes 0.000 claims description 3
- 102100033615 Nucleoprotein TPR Human genes 0.000 claims description 3
- 102100036878 PHD finger protein 20 Human genes 0.000 claims description 3
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims description 3
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims description 3
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 claims description 3
- 102100033566 Polycomb complex protein BMI-1 Human genes 0.000 claims description 3
- 102100031015 Progesterone-induced-blocking factor 1 Human genes 0.000 claims description 3
- 102100033880 Prospero homeobox protein 1 Human genes 0.000 claims description 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 3
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 claims description 3
- 102100029831 Reticulon-4 Human genes 0.000 claims description 3
- 101150006914 TRP1 gene Proteins 0.000 claims description 3
- 102100022224 Y-box-binding protein 1 Human genes 0.000 claims description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims description 3
- 108010014186 ras Proteins Proteins 0.000 claims description 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 2
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims description 2
- 101710177963 Baculoviral IAP repeat-containing protein 7 Proteins 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 101150104494 CAV1 gene Proteins 0.000 claims description 2
- 102000000905 Cadherin Human genes 0.000 claims description 2
- 108050007957 Cadherin Proteins 0.000 claims description 2
- 102000004225 Cathepsin B Human genes 0.000 claims description 2
- 108090000712 Cathepsin B Proteins 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 claims description 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 2
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 claims description 2
- 101001069749 Homo sapiens Prospero homeobox protein 1 Proteins 0.000 claims description 2
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 claims description 2
- 101000825086 Homo sapiens Transcription factor SOX-11 Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102000008730 Nestin Human genes 0.000 claims description 2
- 108010088225 Nestin Proteins 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 101150038998 PLAUR gene Proteins 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 102100022415 Transcription factor SOX-11 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 claims description 2
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 150000002270 gangliosides Chemical class 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000005055 nestin Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 5
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 5
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 5
- 101150005585 E3 gene Proteins 0.000 claims 2
- APHFXDBDLKPMTA-UHFFFAOYSA-N 2-(3-decanoyl-4,5,7-trihydroxynaphthalen-2-yl)acetic acid Chemical compound CCCCCCCCCC(=O)c1c(CC(O)=O)cc2cc(O)cc(O)c2c1O APHFXDBDLKPMTA-UHFFFAOYSA-N 0.000 claims 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 1
- 101150071146 COX2 gene Proteins 0.000 claims 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 claims 1
- 102100024405 GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Human genes 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 claims 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims 1
- 101000981252 Homo sapiens GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 1
- 101000836268 Homo sapiens U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 claims 1
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims 1
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims 1
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 101150000187 PTGS2 gene Proteins 0.000 claims 1
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 claims 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 108010066416 multidrug resistance-associated protein 3 Proteins 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 58
- 241000700605 Viruses Species 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 239000003623 enhancer Substances 0.000 description 19
- 230000010076 replication Effects 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 13
- 101710132601 Capsid protein Proteins 0.000 description 12
- 101710094648 Coat protein Proteins 0.000 description 12
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 12
- 101710125418 Major capsid protein Proteins 0.000 description 12
- 101710141454 Nucleoprotein Proteins 0.000 description 12
- 101710083689 Probable capsid protein Proteins 0.000 description 12
- 229960005486 vaccine Drugs 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 101710145505 Fiber protein Proteins 0.000 description 9
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 9
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 description 8
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 5
- 108060006698 EGF receptor Proteins 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 206010001258 Adenoviral infections Diseases 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 4
- 108010063954 Mucins Proteins 0.000 description 4
- 102000015728 Mucins Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000005975 antitumor immune response Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229940051875 mucins Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000002644 phorbol ester Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102100025278 Coxsackievirus and adenovirus receptor Human genes 0.000 description 3
- 101710176411 Coxsackievirus and adenovirus receptor Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010014967 Ependymoma Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000598171 Human adenovirus sp. Species 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 2
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 101100321993 Drosophila melanogaster pix gene Proteins 0.000 description 2
- 101710092262 G antigen 1 Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101710155188 Hexon-interlacing protein Proteins 0.000 description 2
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 2
- 101100232357 Homo sapiens IL13RA1 gene Proteins 0.000 description 2
- 101100232360 Homo sapiens IL13RA2 gene Proteins 0.000 description 2
- 101000833614 Homo sapiens Interferon-inducible protein AIM2 Proteins 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 2
- 102000008840 Melanoma-associated antigen 1 Human genes 0.000 description 2
- 108050000731 Melanoma-associated antigen 1 Proteins 0.000 description 2
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 2
- 101710204288 Melanoma-associated antigen 3 Proteins 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100024178 Microtubule-associated proteins 1A/1B light chain 3A Human genes 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000007584 Prealbumin Human genes 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108010017007 glucose-regulated proteins Proteins 0.000 description 2
- 101150028578 grp78 gene Proteins 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 102000004233 multidrug resistance protein 3 Human genes 0.000 description 2
- 108090000743 multidrug resistance protein 3 Proteins 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- VVJYUAYZJAKGRQ-BGZDPUMWSA-N 1-[(2r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)C1 VVJYUAYZJAKGRQ-BGZDPUMWSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101100457311 Arabidopsis thaliana MIP1B gene Proteins 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102100031102 C-C motif chemokine 4 Human genes 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 101150047126 CCL4 gene Proteins 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 101150093802 CXCL1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- 102100035888 Caveolin-1 Human genes 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- 101710114676 E1B 55 kDa protein Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101710094396 Hexon protein Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 101000938346 Homo sapiens Ephrin type-A receptor 2 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 1
- 101000804921 Homo sapiens X-ray repair cross-complementing protein 5 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 206010025652 Malignant melanoma in situ Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 101710201349 Metallothionein B Proteins 0.000 description 1
- 102100031347 Metallothionein-2 Human genes 0.000 description 1
- 101710094505 Metallothionein-2 Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100490488 Mus musculus Add3 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108050000980 Prospero homeobox protein 1 Proteins 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- 235000019892 Stellar Nutrition 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 1
- VRGWBRLULZUWAJ-XFFXIZSCSA-N [(2s)-2-[(1r,3z,5s,8z,12z,15s)-5,17-dihydroxy-4,8,12,15-tetramethyl-16-oxo-18-bicyclo[13.3.0]octadeca-3,8,12,17-tetraenyl]propyl] acetate Chemical compound C1\C=C(C)/CC\C=C(C)/CC[C@H](O)\C(C)=C/C[C@@H]2C([C@@H](COC(C)=O)C)=C(O)C(=O)[C@]21C VRGWBRLULZUWAJ-XFFXIZSCSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000014616 embryonal neoplasm Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VRGWBRLULZUWAJ-UHFFFAOYSA-N fusaproliferin Natural products C1C=C(C)CCC=C(C)CCC(O)C(C)=CCC2C(C(COC(C)=O)C)=C(O)C(=O)C21C VRGWBRLULZUWAJ-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000026436 grade III glioma Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000043283 human SERPINE1 Human genes 0.000 description 1
- 102000047299 human XRCC5 Human genes 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 108010077055 methylated bovine serum albumin Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 101150008049 mx gene Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000016359 neuroblastic tumor Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229930185346 proliferin Natural products 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001119—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594005P | 2012-02-02 | 2012-02-02 | |
| US61/594,005 | 2012-02-02 | ||
| PCT/US2013/024506 WO2013116778A2 (en) | 2012-02-02 | 2013-02-01 | Immunogenic adenovirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013214776A1 AU2013214776A1 (en) | 2014-08-21 |
| AU2013214776B2 true AU2013214776B2 (en) | 2017-11-09 |
Family
ID=47714593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013214776A Ceased AU2013214776B2 (en) | 2012-02-02 | 2013-02-01 | Adenoviruses expressing heterologous tumor-associated antigens |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11155599B2 (OSRAM) |
| EP (1) | EP2809788B1 (OSRAM) |
| JP (2) | JP6325459B2 (OSRAM) |
| KR (1) | KR102100092B1 (OSRAM) |
| CN (2) | CN110042086A (OSRAM) |
| AU (1) | AU2013214776B2 (OSRAM) |
| BR (1) | BR112014019049A2 (OSRAM) |
| CA (1) | CA2863523A1 (OSRAM) |
| DK (1) | DK2809788T3 (OSRAM) |
| ES (1) | ES2759785T3 (OSRAM) |
| NZ (1) | NZ628213A (OSRAM) |
| SG (3) | SG11201404495RA (OSRAM) |
| WO (1) | WO2013116778A2 (OSRAM) |
| ZA (1) | ZA201405755B (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2170384T3 (en) | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| DK2806883T3 (da) | 2012-01-25 | 2019-07-22 | Dnatrix Inc | Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation |
| WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| JP6576326B2 (ja) | 2013-03-14 | 2019-09-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
| CA2931322A1 (en) * | 2013-11-22 | 2015-05-28 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| CN104328140B (zh) * | 2014-10-08 | 2018-06-05 | 兰州大学 | 一种高嗜性膀胱癌靶向性肿瘤杀伤腺病毒 |
| JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| KR20170102002A (ko) | 2015-01-09 | 2017-09-06 | 이투빅스 코포레이션 | 에볼라 바이러스 백신접종을 위한 방법 및 조성물 |
| CN104762269A (zh) * | 2015-03-18 | 2015-07-08 | 红土生物技术有限公司 | 一种增强肿瘤抗原免疫原性的新策略及其在肺癌免疫治疗中的应用 |
| WO2016172249A1 (en) * | 2015-04-20 | 2016-10-27 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| US11000560B2 (en) | 2015-05-04 | 2021-05-11 | Vcn Biosciences, S.L. | Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment |
| CN105087648B (zh) * | 2015-06-17 | 2018-05-25 | 深圳益世康宁生物科技有限公司 | 携带mage-a3抗原基因的重组腺相关病毒载体及构建方法与应用 |
| CN105087647B (zh) * | 2015-06-17 | 2018-10-02 | 深圳益世康宁生物科技有限公司 | 一种携带Survivin抗原基因的重组腺相关病毒载体及其构建方法与应用 |
| WO2017112797A1 (en) | 2015-12-22 | 2017-06-29 | Thomas Jefferson University | Intra-lesional cmv-based cancer vaccines |
| FI127460B (en) * | 2016-01-15 | 2018-06-29 | Targovax Oy | Combining adenovirus and chemotherapeutic agents for treating cancer |
| KR20220163505A (ko) | 2016-02-23 | 2022-12-09 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| CN105779480B (zh) * | 2016-03-24 | 2020-03-20 | 成都康景生物科技有限公司 | 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用 |
| DK3436591T5 (da) * | 2016-03-31 | 2024-09-16 | The European Molecular Biology Laboratory | Adenovirale coat-protein-afledte transportvehikler |
| EP3463405A4 (en) * | 2016-05-27 | 2020-02-26 | DNAtrix, Inc. | ADENOVIRUS AND IMMUNO MODULATOR COMBINATION THERAPY |
| JP2019536468A (ja) | 2016-12-12 | 2019-12-19 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍を標的にする合成アデノウイルスおよびその使用 |
| WO2018118967A1 (en) | 2016-12-21 | 2018-06-28 | Memgen, Llc | Armed replication-competent oncolytic adenoviruses |
| KR20190128634A (ko) * | 2017-01-30 | 2019-11-18 | 에피센트알엑스, 인코포레이티드 | 다중 트랜스진 재조합 아데노바이러스 |
| EA201990822A1 (ru) | 2017-04-12 | 2020-01-09 | Эписентарикс, Инк. | Иммуномодулирующие слитые белки |
| EP3714038A1 (en) | 2017-11-22 | 2020-09-30 | Mesoblast International Sàrl | Cellular compositions and methods of treatment i |
| GB201804468D0 (en) | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| AU2019251356B2 (en) | 2018-04-09 | 2025-06-12 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions with enhanced replication properties |
| WO2019237371A1 (zh) * | 2018-06-16 | 2019-12-19 | 深圳市博奥康生物科技有限公司 | 定点插入 ct1.1 基因的 cho 细胞株的构建方法及其用途 |
| CN109081873B (zh) * | 2018-08-10 | 2022-04-22 | 固安鼎泰海规生物科技有限公司 | 一种抗肿瘤重组nmm融合抗原质粒dna疫苗 |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| CN110684800B (zh) * | 2018-11-02 | 2020-11-03 | 深圳益世康宁生物科技有限公司 | 一种携带肿瘤-睾丸抗原10基因的重组腺相关病毒载体及其应用价值 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020259189A1 (zh) * | 2019-06-27 | 2020-12-30 | 北京太东生物科技有限公司 | Sox11作为精神分裂症诊断标记物的应用 |
| CA3149478A1 (en) | 2019-08-05 | 2021-02-11 | Mesoblast International Sarl | Cellular compositions comprising viral vectors and methods of treatment |
| EP3812465A1 (en) * | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
| PH12022551208A1 (en) | 2019-11-18 | 2023-04-24 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
| KR102601875B1 (ko) * | 2020-03-25 | 2023-11-14 | (주)큐리진 | 면역 회피성 항종양 아데노바이러스 |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| CN111850041A (zh) * | 2020-07-30 | 2020-10-30 | 药鼎(北京)国际细胞医学技术有限公司 | 一种治疗肝癌的含il12双顺反子的病毒构建体及其用途和构建方法 |
| EP4192940A1 (en) | 2020-08-10 | 2023-06-14 | Mesoblast International Sárl | Cellular compositions and methods of treatment |
| JP2025536260A (ja) | 2022-10-11 | 2025-11-05 | イェール ユニバーシティー | 細胞透過性抗体の組成物および使用方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009117656A2 (en) * | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5981725A (en) | 1989-09-08 | 1999-11-09 | The Johns Hopkins Univiersity | Structural alterations of the EGF receptor gene in human tumors |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| AU716045B2 (en) | 1994-11-28 | 2000-02-17 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| DE69628744D1 (de) | 1995-04-17 | 2003-07-24 | Univ Texas System Austin Board | Adenovirus helfervirus system |
| US20030026789A1 (en) | 1995-05-03 | 2003-02-06 | Richard J. Gregory | Gene therapy using replication competent targeted adenoviral vectors |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US6080578A (en) | 1996-12-31 | 2000-06-27 | Onyx Pharmaceuticals, Inc. | Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia |
| US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
| WO1998039467A2 (en) | 1997-03-03 | 1998-09-11 | Calydon, Inc. | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof |
| US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
| CA2351587A1 (en) | 1998-11-18 | 2000-05-25 | Canji, Inc. | Viral vectors with late transgene expression |
| GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
| AU767904B2 (en) | 1999-05-12 | 2003-11-27 | Uab Research Foundation, The | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| AU1190901A (en) | 1999-09-30 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Replication selective adenoviruses for use in cancer therapy |
| EP1223947A4 (en) | 1999-10-15 | 2004-12-08 | Canji Inc | TARGETED VECTORS |
| US6756044B1 (en) | 2000-02-09 | 2004-06-29 | Genvec, Inc. | Antigenic complexes and methods |
| AU2001234981A1 (en) | 2000-02-09 | 2001-08-20 | Genvec, Inc. | Adenoviral capsid containing chimeric protein ix |
| US20030138405A1 (en) | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
| US20030211477A1 (en) * | 2002-04-05 | 2003-11-13 | Holmes Kathryn V. | Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening |
| CN104059147A (zh) | 2003-06-27 | 2014-09-24 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| US20070134202A1 (en) | 2003-10-15 | 2007-06-14 | The New Industry Reserch Organization | Cancer gene therapeutic drug |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| CN101607985B (zh) * | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体，包含其的组合物，及其用途 |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| EP2407177A1 (en) * | 2010-07-13 | 2012-01-18 | Institut Gustave Roussy | Adenovirus vaccine vectors |
| EP2383577A1 (en) | 2010-04-30 | 2011-11-02 | Deutsches Krebsforschungszentrum | Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy |
| WO2011140284A2 (en) * | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| DK2806883T3 (da) | 2012-01-25 | 2019-07-22 | Dnatrix Inc | Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation |
| AU2014281826B2 (en) | 2013-06-18 | 2019-10-17 | Board Of Regents, The University Of Texas System | Treatment of brain cancer with oncolytic adenovirus |
-
2013
- 2013-02-01 US US14/375,842 patent/US11155599B2/en active Active
- 2013-02-01 JP JP2014555799A patent/JP6325459B2/ja active Active
- 2013-02-01 BR BR112014019049A patent/BR112014019049A2/pt not_active Application Discontinuation
- 2013-02-01 SG SG11201404495RA patent/SG11201404495RA/en unknown
- 2013-02-01 EP EP13704334.5A patent/EP2809788B1/en active Active
- 2013-02-01 WO PCT/US2013/024506 patent/WO2013116778A2/en not_active Ceased
- 2013-02-01 ES ES13704334T patent/ES2759785T3/es active Active
- 2013-02-01 CN CN201910116066.XA patent/CN110042086A/zh active Pending
- 2013-02-01 CN CN201380017639.4A patent/CN104271748B9/zh not_active Expired - Fee Related
- 2013-02-01 KR KR1020147024570A patent/KR102100092B1/ko not_active Expired - Fee Related
- 2013-02-01 SG SG10201913795TA patent/SG10201913795TA/en unknown
- 2013-02-01 SG SG10201606356YA patent/SG10201606356YA/en unknown
- 2013-02-01 NZ NZ628213A patent/NZ628213A/en not_active IP Right Cessation
- 2013-02-01 AU AU2013214776A patent/AU2013214776B2/en not_active Ceased
- 2013-02-01 DK DK13704334T patent/DK2809788T3/da active
- 2013-02-01 CA CA2863523A patent/CA2863523A1/en not_active Abandoned
-
2014
- 2014-08-05 ZA ZA2014/05755A patent/ZA201405755B/en unknown
-
2018
- 2018-04-12 JP JP2018076878A patent/JP2018138033A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009117656A2 (en) * | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014019049A2 (pt) | 2017-07-04 |
| EP2809788A2 (en) | 2014-12-10 |
| WO2013116778A2 (en) | 2013-08-08 |
| ES2759785T3 (es) | 2020-05-12 |
| JP2018138033A (ja) | 2018-09-06 |
| ZA201405755B (en) | 2020-05-27 |
| CA2863523A1 (en) | 2013-08-08 |
| CN110042086A (zh) | 2019-07-23 |
| SG10201606356YA (en) | 2016-09-29 |
| CN104271748B (zh) | 2019-03-29 |
| KR20140125834A (ko) | 2014-10-29 |
| SG11201404495RA (en) | 2014-10-30 |
| CN104271748A (zh) | 2015-01-07 |
| JP2015506704A (ja) | 2015-03-05 |
| AU2013214776A1 (en) | 2014-08-21 |
| EP2809788B1 (en) | 2019-09-04 |
| DK2809788T3 (da) | 2019-12-09 |
| SG10201913795TA (en) | 2020-03-30 |
| CN104271748B9 (zh) | 2019-05-24 |
| HK1205182A1 (en) | 2015-12-11 |
| JP6325459B2 (ja) | 2018-05-16 |
| WO2013116778A3 (en) | 2013-12-19 |
| US20140377294A1 (en) | 2014-12-25 |
| NZ628213A (en) | 2016-10-28 |
| US11155599B2 (en) | 2021-10-26 |
| KR102100092B1 (ko) | 2020-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013214776B2 (en) | Adenoviruses expressing heterologous tumor-associated antigens | |
| US20250171745A1 (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| KR102351555B1 (ko) | Hpv 및 관련 질환용 면역 증강 치료 백신 | |
| EP3269387B1 (en) | Polynucleotides and polypeptides for treating oncogenic viral polypeptide positive tumors | |
| JP2018519847A5 (OSRAM) | ||
| JP2015523412A (ja) | 腫瘍細胞、ＧＭ‐ＣＳＦのトランスジェニック発現を伴う腫瘍溶解性ウイルスベクター、および免疫チェックポイントモジュレーターなどの成分の少なくとも２種または全３種の同時投与により作られる生のｉｎｖｉｖｏ腫瘍特異的がんワクチンシステム | |
| JP2020531524A (ja) | 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法 | |
| JP7670705B2 (ja) | ４－１ｂｂｌアジュバント添加した組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）の医学的使用 | |
| WO2003031602A1 (en) | The oncolytic microorganisms expressing hsp and uses thereof | |
| Blaszczyk-Thurin et al. | A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma | |
| HK1205182B (en) | Adenoviruses expressing heterologous tumor-associated antigens | |
| HK40012146A (zh) | 表达异源肿瘤相关抗原的腺病毒 | |
| Nemeckova et al. | Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules | |
| US20250049903A1 (en) | Therapy for Modulating Immune Response with Recombinant MVA Encoding IL-12 | |
| CN116948005A (zh) | 一种病毒递送的新型细胞因子及在肿瘤治疗中的应用 | |
| HK40030022A (en) | Adenovirus expressing immune cell stimulatory receptor agonist(s) | |
| Springer et al. | 707. Characterization of the Complex Physiological Response to Constitutive VEGF Gene Expression | |
| IL321887A (en) | Recombinantly modified Sarna (vrp) for cancer vaccine | |
| Rodriguez-Madoz et al. | 302. Semliki Forest Virus Mediated Intratumoral Expression of IL 12 Induces Tumor Regression in a Mouse Model of Colon Adenocarcinoma | |
| Birmingham | 265. ImmunoVexEx Vivo: A Herpes Simplex Virus-Based, Dendritic Cell-Mediated Anti-Cancer Vaccine Platform |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |